Skip to Content

Generic Tavalisse Availability

Last updated on Sep 8, 2021.

Tavalisse is a brand name of fostamatinib, approved by the FDA in the following formulation(s):

TAVALISSE (fostamatinib disodium - tablet;oral)

  • Manufacturer: RIGEL PHARMS INC
    Approval date: April 17, 2018
    Strength(s): EQ 100MG BASE [RLD], EQ 150MG BASE [RLD]

Has a generic version of Tavalisse been approved?

No. There is currently no therapeutically equivalent version of Tavalisse available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tavalisse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 7,449,458
    Issued: November 11, 2008
    Inventor(s): Bhamidipati; Somasekhar & Singh; Rajinder & Stella; Valentino J. & Sun; Thomas
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods for using these compounds in a variety of applications including treatment of autoimmune diseases.

    Patent expiration dates:

    • September 4, 2026
      ✓ 
      Drug substance
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 7,538,108
    Issued: May 26, 2009
    Inventor(s): Singh; Rajinder & Masuda; Esteban & Bhamidipati; Somasekhar & Sun; Thomas & Stella; Valentino J.
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds of structural formula shown below, compositions comprising these compounds, intermediates and methods for synthesizing these compounds, and methods of using these compounds in a variety of applications including treatment of autoimmune diseases.

    Patent expiration dates:

    • March 28, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
      ✓ 
      Drug substance
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 7,989,448
    Issued: August 2, 2011
    Inventor(s): Singh; Rajinder & Bhamidipati; Somasekhar & Masuda; Esteban
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides compounds of the following formula, and methods of using the compounds to inhibit cellular degranulation and to treat diseases associated therewith.

    Patent expiration dates:

    • June 12, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
      ✓ 
      Drug substance
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 8,163,902
    Issued: April 24, 2012
    Inventor(s): Bhamidipati; Somasekhar & Singh; Rajinder & Sun; Thomas & Masuda; Esteban
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • June 17, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
      ✓ 
      Drug substance
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 8,211,889
    Issued: July 3, 2012
    Inventor(s): Singh; Rajinder & Bhamidipati; Somasekhar & Sun; Thomas & Stella; Valentino J.
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • January 19, 2026
      ✓ 
      Drug substance
  • Wet granulation using a water sequestering agent
    Patent 8,263,122
    Issued: September 11, 2012
    Inventor(s): Sun; Thomas & Lo; Ray
    Assignee(s): Rigel Pharmaceuticals, Inc.

    Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.

    Patent expiration dates:

    • November 24, 2030
      ✓ 
      Drug product
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 8,445,485
    Issued: May 21, 2013
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • June 17, 2026
      ✓ 
      Drug product
  • Wet granulation using a water sequestering agent
    Patent 8,652,492
    Issued: February 18, 2014
    Assignee(s): Rigel Pharmaceutical, Inc.

    Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.

    Patent expiration dates:

    • November 6, 2028
      ✓ 
      Drug product
  • (Trimethoxyphenylamino) pyrimidinyl formulations
    Patent 8,771,648
    Issued: July 8, 2014
    Assignee(s): Rigel Pharmaceuticals, Inc.

    There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

    Patent expiration dates:

    • July 27, 2032
      ✓ 
      Drug product
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 8,912,170
    Issued: December 16, 2014
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • June 17, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
  • (trimethoxyphenylamino) pyrimidinyl formulations
    Patent 8,951,504
    Issued: February 10, 2015
    Assignee(s): Rigel Pharmaceuticals, Inc.

    There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

    Patent expiration dates:

    • July 27, 2032
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 9,266,912
    Issued: February 23, 2016
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • January 19, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 9,283,238
    Issued: March 15, 2016
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • June 17, 2026
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent 9,737,554
    Issued: August 22, 2017
    Assignee(s): Rigel Pharmaceuticals, Inc.

    The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

    Patent expiration dates:

    • January 19, 2026
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • April 17, 2023 - NEW CHEMICAL ENTITY
    • April 17, 2025 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.